Articles tagged with Prostate Cancer
A phase 3 clinical trial found that ipilimumab improved progression-free survival by two to three times in patients with metastasized, castration-resistant prostate cancer. The treatment also showed overall survival benefits compared to the placebo arm.
Cryoablation, a less-invasive treatment technique, offers a promising alternative to surgery for prostate cancer control. According to the study, cryoablation provided a high rate of effective prostate cancer control in 82% of patients at 18-month follow-up.
A major trial shows olaparib, a PARP inhibitor, is more effective than modern hormone treatments in slowing down prostate cancer growth and spread. Patients with genetic alterations in DNA repair genes who received olaparib had a median overall survival of 19.1 months.
The PROfound trial demonstrates the efficacy of PARP inhibitor olaparib in treating metastatic castration-resistant prostate cancer (mCRPC) with at least one alteration in BRCA1 or BRCA2 genes. Olaparib significantly improves overall survival, particularly in patients with alterations in these genes.
A new US study finds that HIFU provides adequate control of prostate cancer while avoiding significant side effects, with nearly 90% of men able to avoid or delay radical treatment. The non-invasive therapy also preserves sexual function and urinary symptoms, with no serious complications reported.
A new study suggests that focal high-intensity focused ultrasound (HIFU) ablation is an effective alternative to surgery or radiation for treating prostate cancer. The procedure carries a low risk of complication and helps preserve quality of life, with no significant decrease in sexual function or urinary incontinence.
A study published in Cancer highlights racial disparities in prostate cancer deaths, with Black men facing a higher risk of death compared to white men. The analysis found that socioeconomic factors, such as education and median household income, contributed significantly to these disparities.
A new study by Umeå University researchers sheds light on the molecular mechanisms of prostate cancer cell mobilization. They found that an amino acid in TGF-β signalling molecule Smad7 enables cancer cells to spread and form life-threatening metastases.
A study of over 200,000 UK men found a link between central adiposity and the risk of death from prostate cancer. Those with larger waist circumferences were more likely to die from prostate cancer than those with smaller waist sizes.
A new device developed by Dartmouth engineers has the potential to improve patient outcomes for prostate cancer patients who undergo radical prostatectomy. The device, which uses microendoscopic electrical impedance sensing probe technology, aims to detect positive surgical margins and prevent disease recurrence.
A targeted therapy called rucaparib has been successfully used to treat men with advanced prostate cancer who have mutated BRCA1/BRCA2 genes. The treatment resulted in a 41% objective response rate and improvements in prostate-specific antigen levels for over half of the patients.
A new study by Brigham and Women's Hospital found that delaying radiation therapy for men with unfavorable intermediate-risk or high-risk localized prostate cancer, who are receiving radiation and hormone therapy, is unlikely to impact survival. This flexibility in radiation timing could help patients minimize exposure to COVID-19 by s...
A study examined the association between radiotherapy timing and overall survival in patients with prostate cancer. The analysis of National Cancer Database data found that delaying radiotherapy relative to androgen deprivation therapy was associated with improved overall survival.
A new study found that acute exercise maintains the immune system's natural killer cell count at a normal level in prostate cancer survivors. Exercise appears to be safe and beneficial for these individuals, with no significant alterations in immune cell mobilization during treatment.
A recent study found an association between a healthy diet and reduced prostate cancer risk, as well as an increased risk with diets rich in sweets and beverages. The research team analyzed data from over 1,000 participants and identified key dietary patterns that may inform prevention strategies for prostate cancer.
A study published in The Lancet Digital Health demonstrates an AI program's highest accuracy to date in recognizing and characterizing prostate cancer. The algorithm achieved 98% sensitivity and 97% specificity in detecting prostate cancer, surpassing previously reported results.
A genomic signature associates with differential expression of glucose transporters and hexokinase proteins in prostate cancers with low PSMA expression. This allows for improved uptake of 18F-FDG compared to PSMA-targeted radioligands, making it an attractive imaging tool for neuroendocrine prostate cancer patients.
A study published in Nature Genetics confirms decades-old hypothesis that metastatic disease hijacks tissue-specific developmental programs. The researchers analyzed epigenetic data from patient-derived samples and identified thousands of sites across the prostate genome regulating gene expression.
BRD4 protein regulates key proteins contributing to prostate cancer progression, suggesting new therapeutic target. Current treatments for castration-resistant prostate cancer are limited and focus on suppressing tumor cells' reliance on androgen receptor signaling.
A global methodology has been developed to help decide when to treat prostate cancer, providing a single standard for estimating tumour aggressiveness. The GAP3 consortium's analysis of 14,380 patients reveals that certain factors can predict cancer development, enabling more informed treatment decisions.
A major study conducted by patients themselves reports significant numbers struggling with continence and sexual problems after prostate cancer treatment. The Europa Uomo Patient Reported Outcomes Study found that any treatment apart from active surveillance negatively affects quality of life.
Researchers found the AZIN1 gene associated with metastatic prostate cancer, with reduced expression leading to fewer metastases. Further investigation is needed to confirm findings in all prostate cancers.
Researchers at Baylor College of Medicine have discovered a new site on the androgen receptor that interacts with activity-enhancing coactivators, driving prostate cancer growth. The study's findings provide insights into the design of future treatments for this devastating condition.
A multicenter trial found that PSMA PET/CT identified disease in over half of patients with negative conventional imaging, leading to changes in management in 66% of cases. The most common changes were conversion to surgery or radiation, or addition of nodal-directed therapy.
A literature review found significant evidence supporting the causal role of high-risk HPV types 16 and 18 in prostate cancer. The authors suggest that HPV vaccination may help prevent prostate cancer development, particularly in countries with high mortality rates from cervical cancer.
Researchers developed a novel radioiodinated PSMA-targeting radiopharmaceutical that can be produced in high yields without generating volatile byproducts. The agent shows exceptional effectiveness for precision diagnosis and treatment of prostate cancer in preclinical studies, targeting prostate-specific membrane antigen (PSMA).
A new study has identified genes more frequently altered in prostate tumors from men of African ancestry compared to other racial groups. The research found no significant differences in frequencies of mutations in genes important for current prostate cancer therapies, but suggests that precision medicine approaches can be effective if...
Researchers used ChIA-PET to map associations between proteins and DNA in prostate cancer cells, discovering hubs of interacting enhancers that regulate gene expression. These findings may lead to novel treatments for the most common type of prostate cancer.
A recent study published in Radiology found that prostate MRI quality is highly variable across institutions, with a significant impact on cancer detection and treatment outcomes. The study's findings suggest that improved standardization and training are needed to ensure consistent imaging results and better patient care.
Researchers at the University of South Australia have developed a novel formulation of the prostate cancer drug abiraterone acetate, improving its effectiveness by 40%. The new oral formulation reduces side effects and allows for a smaller dose to be effective without fasting.
Key recommendations from the Philadelphia Prostate Cancer Consensus Conference include performing genetic testing for all men with metastatic prostate cancer and those with a family history of hereditary cancers. Recommended genes for testing include BRCA2, BRCA1, and DNA mismatch repair genes. Genetic testing is also recommended to in...
Researchers identified four subtypes of prostate cancer with distinct characteristics, affecting treatment strategies and potentially improving patient outcomes. The study's findings suggest that one subtype requires intensified treatments while another is less aggressive, paving the way for more targeted therapies.
Researchers have identified a variant in the genome associated with higher risk of prostate cancer in African American men. This variant is found in about 12% of men of African ancestry and increases their risk two-fold.
A UK-first pilot study has shown that genetic screening for prostate cancer can safely identify undiagnosed cases in approximately one-third of otherwise healthy men. The study involved testing for 130 DNA changes and found that population screening was effective at detecting new cancers in this high-risk group.
A new test developed by researchers at the University of Birmingham uses complex sugars to detect prostate cancer earlier and with greater accuracy. The test identifies glycans in blood that are associated with different cancers, allowing for more precise diagnoses.
Olaparib, a PARP inhibitor, targets genetic mutations in advanced prostate cancer patients with BRCA1 and BRCA2. The FDA approved the drug for homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer.
A new mathematical model predicts prostate cancer tumor growth and invasiveness based on stromal ecology, revealing that highly reactive stroma drives aggressive tumors. The model was validated in animal models and patients, suggesting improved prognosis with ecological metrics.
Researchers have found that the new radiotracer 18F-PSMA-1007 offers advantages over established agent 68Ga-PSMA-11 in staging prostate cancer. The study showed near-equal performance between the two tracers, with 18F-PSMA-1007 detecting additional lesions in four patients.
A study of 4532 men found that those on androgen-deprivation therapies had a four-fold reduced risk of COVID-19 infections compared to those not on ADT. The researchers suggest that even non-prostate cancer patients at high risk could take ADT for prevention.
Researchers at Memorial Sloan Kettering Cancer Center discovered that nearly all cells in the prostate gland contribute to its regrowth after androgen-deprivation therapy. Luminal cells acquire stem-like properties without hormone influence, leading to implications for prostate cancer treatment and potential therapeutic strategies.
A clinical trial has identified a gene program active in metastatic prostate cancers that failed to respond to enzalutamide treatment. The study found that these tumors had lower androgen receptor activity and higher stemness, making them more adaptable and resistant to treatment.
The NCCN Guidelines for Patients are among the most trustworthy resources for patients and caregivers seeking information on prostate cancer. The guidelines, written in an easy-to-learn format, provide essential information on diagnosis and treatment.
Researchers developed a mathematical model that forecasts patient responses to intermittent androgen deprivation therapy based on changing levels of the biomarker PSA. The model predicted 89% accuracy in developing patient resistance, enabling personalized treatment options.
A Phase II trial found patients with metastatic castration-resistant prostate cancer who showed active T-cell responses in their tumors experienced prolonged survival after ipilimumab treatment. Researchers identified biomarkers associated with improved responses, including higher T-cell density and interferon-γ signaling.
A recent study analyzing nearly 230,000 men found significant racial disparities in prostate cancer survival rates across the United States. The research identified geographic areas with lower survival rates for certain racial groups compared to white patients.
The iPS87 cell line is characterized as a cancer-inducing, stem cell-like cell line that can be used to develop novel treatments for prostate cancer. After 8 transfers, the cultured cells lost their tumor-inducing capability and stem cell marker expression.
A randomized trial of high-dose targeted radiation versus observation found no significant difference in progression prevention among 54 men with recurrent hormone-sensitive prostate cancer. The study suggests that observation may be a viable alternative to radiation therapy for this patient population.
Researchers found that overexpression of hPCL3S promotes proliferation, anchorage-independent growth, and migration in human LNCaP prostate cancer cells. Silencing of endogenous hPCL3S in DU145 and PC3 prostate cancer cells impairs these effects.
Researchers analyzed DNA haplotypes associated with hereditary prostate cancer (HPC) and found that one mutation increased risk by 22-fold. The study identified 183 variants linked to HPC at genome-wide significance, shedding light on the genetic factors contributing to disease.
A new molecular imaging technique, PSMA PET/CT, is more accurate than conventional medical imaging in detecting prostate cancer spread. The approach helps doctors tailor treatments by identifying disease extent at diagnosis.
The study discovered a link between the amount of DESNT subtype cells in a tumor sample and disease progression. The findings also identified three new subtypes of prostate cancer that could be used to stratify patients for different treatments.
Researchers found African-American men are less likely to use a more targeted biopsy option for prostate cancer, which could lead to overdiagnosis and underdiagnosis of the disease. The study suggests that socioeconomic or cultural biases may be influencing this disparity.
A study led by James Cook University found that supervised exercise sessions can reduce the negative side effects of Androgen Deprivation Therapy (ADT) in prostate cancer patients. The research showed sustained benefits in cardiovascular risk profile and quality of life, but not in cardiopulmonary fitness and fatigue.
Researchers developed a microfluidics device that isolates cancer cells from urine, achieving high detection rates of up to 85% and 86% for localized cancer cases. The new method provides an alternative to invasive tissue biopsies and blood tests with false positive results.
Researchers have developed a new method to identify biomarkers for prostate cancer in urine samples, which can help reduce unnecessary biopsies. The test combines multiple components of urine and uses machine learning techniques to accurately predict disease status without invasive biopsy.
Researchers at UCL have developed a new test to identify the earliest genetic changes of prostate cancer in blood plasma. The process, known as DNA methylation, uses Next Generation Sequencing (NGS) to establish if prostate cancer DNA is present in blood plasma.
Researchers used AI to analyze digitized images of cancer tissues and found critical variations between black and white male patients, which could improve care for black patients with prostate cancer. The study suggests that there are biological differences in the disease that cannot be explained by other disparities.
A combination of MRI and traditional biopsies significantly detects aggressive prostate cancers than standard biopsy alone. This method enables better diagnosis and reduces unnecessary treatment for slow-growing cancers.
A pilot study at USC found that an MAO inhibitor called phenelzine can help patients with recurrent prostate cancer by disrupting tumor growth pathways. The drug has fewer side effects compared to standard hormone therapy treatments.
A recent study published in Annals of Oncology found that excess body fat in middle to late adulthood increases the risk of developing advanced prostate cancer. Maintaining a healthy weight through healthy eating and exercise can help reduce this risk.